The Fastest Growing Cord Blood Bank, Americord Registry, Backs Up Its Product Offering with the First Ever $80,000 Cord Blood Quality Product Guarantee

Share Article

Management Predicts that Cord Blood Industry Stalwarts ViaCord and CBR (aka "Cord Blood Registry") Will Soon Follow Suit

Cord Blood

Cord Blood - Americord

We stand behind our words and back them up with our cord blood quality service guarantee, the best in the industry.

After KKR invested $65 million in China Cord Blood in April, investors again began to take notice of this small but rapidly growing industry. One cord blood banking upstart, Americord Registry, meanwhile quietly continues to gain traction and take market share from the leading cord blood companies.

While many cord blood companies suffered during the recession, in part due to recession induced declines in birth rates (see recent NY Times Article), Americord quickly gained traction. Management believes that since the beginning of 2011, the company has been growing faster than all of the other companies in the cord blood space, growing at an annual growth rate of over 100%. Its strategy? Spend less on marketing and invest meaningfully in research and development.

According to CEO Martin Smithmyer, "Our competitors, we estimate, have spent approximately 50% of their incoming revenue on sales and marketing expenditures. This is a disservice to their clients, especially during a recession, since it costs pregnant mothers and expecting fathers twice as much, and doesn't add any value to what the clients are purchasing." More importantly, however, is Americord's commitment to quality. "We stand behind our words and back them up with our cord blood quality service guarantee, which we believe to be the best in the industry."

Americord is continuing to up the ante with the recent launch of its cord tissue banking and with today's Quality Guarantee announcement. This $80,000 cord blood Quality Guarantee, management believes, is the largest cord blood guarantee ever. If a cord blood client's stored cord blood is used in a stem cell transplant and fails to engraft, Americord will pay up to $80,000 to defray the cost of the procurement of an alternate stem cell source if medically indicated. Specific conditions may be found on the company's website.

For more information about Americord Registry, or to speak with Mr. Smithmyer, please email pr(at)cordadvantage(dot)com.

About Americord Registry             
Americord Registry, a leader in the advancement of cord blood, cord tissue and placenta banking, collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 75 blood diseases such as sickle cell anemia and leukemia.

Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company’s laboratories are CLIA Certified, accredited by the AABB and comply with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord Registry’s website at for more information.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website